Royal Bank of Canada
INTS icon

Royal Bank of Canada’s Intensity Therapeutics INTS Stock Holding History

Royal Bank of Canada’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3
Closed – – 7119
2024
Q2 		$0 Buy
+3
New +$340 ﹤0.01% 7280
2024
Q1 		– Sell
-1
Closed -$120 – 7272
2023
Q4 		$0 Buy
+1
New +$105 ﹤0.01% 7333

Other funds holding INTS

SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
OCPWS
One Charles Private Wealth Services Hingham, Massachusetts $434M AUM 22.37% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada's INTS Position: Q3 2024 in Review

Royal Bank of Canada sold out of Intensity Therapeutics (INTS) in Q3 2024, closing a stake of 3 shares.

Royal Bank of Canada first reported a position in INTS in Q4 2023 and held it in 2 quarters. The position peaked at $0 in Q2 2024. 20 funds tracked by Wall St. Rank hold INTS as of Q3 2024.

  • Royal Bank of Canada reported no remaining Intensity Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 3 Intensity Therapeutics shares in Q3 2024.
  • Royal Bank of Canada first reported a position in Intensity Therapeutics in Q4 2023 and held it in 2 quarters.
  • Royal Bank of Canada's Intensity Therapeutics position peaked at $0 in Q2 2024.
  • 20 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.